GSA Capital Partners LLP bought a new stake in Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 287,756 shares of the company's stock, valued at approximately $751,000. GSA Capital Partners LLP owned about 0.55% of Kodiak Sciences at the end of the most recent reporting period.
Other hedge funds also recently added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new stake in shares of Kodiak Sciences in the 3rd quarter valued at approximately $33,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Kodiak Sciences in the first quarter valued at approximately $68,000. Meeder Asset Management Inc. acquired a new position in Kodiak Sciences during the second quarter worth $36,000. Sanctuary Advisors LLC purchased a new position in shares of Kodiak Sciences during the second quarter worth $36,000. Finally, State Board of Administration of Florida Retirement System acquired a new stake in shares of Kodiak Sciences in the first quarter valued at $86,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.
Kodiak Sciences Price Performance
Shares of Kodiak Sciences stock traded up $0.13 during trading hours on Monday, hitting $5.66. The company had a trading volume of 828,276 shares, compared to its average volume of 480,158. Kodiak Sciences Inc. has a twelve month low of $2.18 and a twelve month high of $7.77. The company has a market cap of $297.83 million, a P/E ratio of -1.55 and a beta of 2.26. The company's 50-day moving average is $3.42 and its two-hundred day moving average is $3.06.
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on the company. HC Wainwright reissued a "neutral" rating and set a $3.00 target price on shares of Kodiak Sciences in a research note on Friday. Barclays lifted their price objective on Kodiak Sciences from $3.00 to $4.00 and gave the company an "underweight" rating in a research note on Friday.
Get Our Latest Analysis on KOD
Kodiak Sciences Profile
(
Free Report)
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
Read More
Before you consider Kodiak Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.
While Kodiak Sciences currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
